NCT06510322View on ClinicalTrials.gov

Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Vascular Diseases
Interventions
DRUG

Sildenafil

Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.

OTHER

Placebo

Matched capsule not containing any medication

Trial Locations (1)

10461

RECRUITING

Montefiore Medical Center, The Bronx

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Montefiore Medical Center

OTHER